International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
D'Amico, Ferdinando (Humanitas University. Department of Biomedical Sciences)
Rubin, David T. (University of Chicago. Department of Medicine)
Kotze, Paulo Gustavo (Catholic University or Paraná)
Magro, Fernando (Centro Hospitalar São João)
Siegmund, Britta (Charité - Universitätsmedizin Berlin)
Kobayashi, Taku (Kitasato University. Kitasato Institute Hospital)
Olivera, Pablo A. (Centro de Educación Médica e Investigaciones Clínicas (Buenos Aires))
Bossuyt, Peter (Imelda General Hospital)
Pouillon, Lieven (Imelda General Hospital)
Louis, Edouard (Liège University Hospital (Bèlgica))
Domènech, Eugeni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Ghosh, Subrata (University of Birmingham)
Danese, Silvio (Humanitas University. Department of Biomedical Sciences)
Peyrin-Biroulet, Laurent (University of Lorraine)
Universitat Autònoma de Barcelona. Departament de Medicina

Data:	2021
Resum:	Fecal calprotectin (FC) is a non-invasive marker of gut inflammation which is frequently used to guide therapeutic decisions in patients with inflammatory bowel diseases (IBD). Each step of FC measurement can influence the results, leading to misinterpretations and potentially impacting the management of IBD patients. To date, there is high heterogeneity between FC measurements and no current method is universally accepted as a standard. Our aim was to provide clear position statementsabout the pre-analytical and the analytical phases of FC measurement to homogenize FC levels and to minimize variability and risk of misinterpretation through aninternational consensus. Fourteen physicians with expertise in the field of IBD and FC from 11 countries attended a virtual international consensus meeting on July 17th, 2020. A systematic literature was conducted and the literature evidence was shared and discussedamong the participants. Statements were formulated, discussed, and voted. Statements were considered approved if all participants agreed. Nine statements were formulated and approved. Based on the available evidence, quantitative tests should be preferred for measuring FC. Furthermore, FC measurement, if possible, should always be performed with the same method and factors influencing FC levels should be taken into account when interpreting the results. FC has an increasingly important role in the management of patients with IBD. However, large multicenter studies should be conducted to define the reproducibility and to confirm the diagnostic accuracy of the available FC tests. FC concentrations guide clinicians' treatment decisions. Our statements have a relevant impact in daily practice and could be applied in clinical trials to standardize FC measurement. Summarise the established knowledge on this subject. What are the significant findings of this study?.
Nota:	Funding information: Amgen
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Fecal calprotectin ; Inflammatory bowel disease ; Measurement ; Standardization
Publicat a:	United European Gastroenterology Journal, Vol. 9 (may 2021) , p. 451-460, ISSN 2050-6414

DOI: 10.1002/ueg2.12069
PMID: 33961734

10 p, 460.1 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats